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OBJECTIVES: To develop and validate a model to predict
1-year risk of end-stage renal disease (ESRD) in elderly
subjects with advanced chronic kidney disease (CKD).
DESIGN: Retrospective.
SETTING: Veterans Affairs Medical Center.
PARTICIPANTS: Individuals aged 65 and older with
CKD with an estimated glomerular filtration rate (eGFR)
less than 30 mL/min per 1.73 m2.
MEASUREMENTS: The outcome was ESRD within
1 year of the index eGFR. Cox regression was used to
develop a predictive model (Veterans Affairs (VA) risk
score) that was validated in a separate cohort.
RESULTS: Of the 1,866 participants in the developmental
cohort, 77 developed ESRD. Risk factors for ESRD in the
final model were age, congestive heart failure, systolic
blood pressure, eGFR, potassium, and albumin. In the vali-
dation cohort, the C index for the VA risk score was
0.823. The risk for developing ESRD at 1 year from low-
est to highest tertile was 0.08%, 2.7%, and 11.3%
(P < .001). The C-index for the recently published Tangri
model in the validation cohort was 0.780.
CONCLUSION: A new model using commonly available
clinical measures shows excellent ability to predict the
onset of ESRD within the next year in elderly adults. The
Tangri model also had good predictive ability. Individuals
and physicians can use these risk models to inform deci-
sions regarding preparation for renal replacement therapy
in individuals with advanced CKD. J Am Geriatr Soc
61:762–768, 2013.
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Chronic kidney disease (CKD) affects more than 26million Americans.1 The prevalence of CKD has
increased in recent years, particularly in the elderly popu-
lation.1 Approximately half of all Americans aged 70 and
older have been diagnosed with CKD.1 Individuals with
CKD are at risk for metabolic complications, cardiovascu-
lar disease, end-stage renal disease (ESRD), and all-cause
mortality.2,3 The risk of ESRD and all-cause mortality that
accompanies CKD differs according to age; older individu-
als are more likely to die than progress to ESRD.4,5 The
rate of decline in renal function also varies and is affected
by individual characteristics.6 This variation in risk has
important implications for individuals with advanced CKD
in whom preparation for renal replacement therapy is an
essential aspect of management.
The National Kidney Foundation Kidney Disease Out-
comes Quality Initiative guidelines recommend preparation
for renal replacement therapy in individuals with an esti-
mated glomerular filtration rate (eGFR) of less than
30 mL/min per 1.73 m2.7 Before initiating dialysis access
placement, individuals should receive education regarding
ESRD treatment options, including no treatment, perito-
neal dialysis, transplantation, and hemodialysis. For indi-
viduals choosing hemodialysis (>90% in the United
States), the guidelines recommend placement of a fistula
6 months before initiation of dialysis.7 Although the
timing of initiation of dialysis is controversial and has
changed recently, no specific tools are available to help
physicians and individuals with the difficult decisions
related to preparation for hemodialysis. Planning for
hemodialysis access takes approximately 1 year and
includes referral to vascular surgery, vein mapping, sur-
gery, and access maturation. Therefore, a tool to predict
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1-year risk of ESRD would be clinically useful, especially
in elderly adults, given their lower overall risk of ESRD.
Elderly adults at low risk for ESRD could be spared
unnecessary tests and surgical procedures, whereas those
at high risk could be referred for access placement.
Previous studies have evaluated risk factors for ESRD
in various populations, but no prediction model is avail-
able to evaluate risk for ESRD at 1 year in older adults
with advanced CKD. The purpose of this study was to
develop and validate a prediction model for ESRD at
1 year in elderly adults with advanced CKD.
METHODS
A retrospective study was performed at the Louis Stokes
Cleveland Veterans Affairs (VA) Medical Center. The insti-
tutional review board approved the study. Inclusion crite-
ria were aged 65 and older and an index outpatient eGFR
of less than 30 mL/min per 1.73 m2 between January 1,
2002, and January 1, 2009. Because individuals are not
likely referred for renal replacement planning on the
basis of one low eGFR, an outpatient eGFR of less than
30 mL/min per 1.73 m2 in the year before the index eGFR
was required. Finally, to fulfill criteria for CKD, an outpa-
tient eGFR of less than 60 mL/min per 1.73 m2 between
90 and 730 days before the index GFR was also required.8
A single eGFR of less than 30 mL/min per 1.73 m2
between 90 and 365 days before the index eGFR could
fulfill the latter two criteria. The first eligible index eGFR
was chosen for individuals with multiple eligible eGFR
values. Individuals with a kidney transplant and those
receiving renal replacement therapy were excluded. The
developmental cohort included individuals seen in
Cleveland. A separate validation cohort included all other
individuals from the Greater Ohio Veterans Integrated
Service Network (VISN) 10.
Baseline data were collected from the VISN 10 data-
base and included demographic information, blood pres-
sure (BP) measurements, past medical history, medication
use, and laboratory values. All data were obtained from
the 2 years before the index eGFR. When multiple
measurements were present, the most-recent value was
selected. Proteinuria was defined as an albumin to creati-
nine ratio greater than 300 mg/g, a urinalysis with 2 or
greater proteinuria, or a urinalysis with more than 30
mg/dL of protein. Comorbidities were defined as diabetes
mellitus (2 International Classification of Diseases,
Ninth Revision (ICD-9) codes 250–250.99 or  2 diabetic
medications filled before the index eGFR), coronary artery
disease ( 2 ICD-9 codes 410–414.99, 429.2), cancer ( 2
ICD-9 codes 140–208, 230–234, V10), congestive heart
failure (CHF; 2 ICD-9 codes 398.91, 402.01, 402.11,
402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93,
414.8, or between 428 and 428.99), and chronic obstruc-
tive pulmonary disease (COPD; 2 ICD-9 codes
491–494, 496, 510). VA ICD-9 codes have been shown to
have moderate sensitivity (>80%) and excellent specificity
(>90%).9,10
The primary outcome was ESRD within 1 year of the
index eGFR. ESRD was defined as the need for chronic
renal replacement therapy as determined according to
chart review blinded to the predictors in the final model.
Individuals were not considered to require chronic renal
replacement therapy in instances of acute kidney injury if
they recovered renal function or did not survive to hospital
discharge. Chart reviews were conducted to evaluate eligi-
bility and to ascertain the date of initiation of dialysis. The
medical record was reviewed to adjudicate ESRD for all
subjects with a hemodialysis note, an ICD-9 code for
ESRD (585.5, 585.6, 792.5, V42, V45.1, V56, V56.1,
V56.2, V56.31, V56.32, or V56.8), an eGFR of less than
15 mL/min per 1.73 m2 (at baseline or during follow-up),
or previously identified as having ESRD in the database.
The date of initiation of dialysis was the date of the first
chronic dialysis at the VA or the approximate date of initi-
ation as determined from clinical notes if dialysis was
started at an outside facility. Initiation of dialysis was at
the discretion of the individual and the nephrologist and
was not affected by this retrospective study. No subjects
received a kidney transplant.
Statistical Analyses
Baseline characteristics in the developmental and valida-
tion samples are described using summary statistics. Time
to ESRD was determined according to chart review as
described above, with right censoring if subjects died or
did not have ESRD. A final prediction model, the VA risk
score, was developed using Cox proportional hazards
models. Variables associated with risk of ESRD in unad-
justed analyses were included in the base model, and age,
sex, race, diabetes mellitus, CHF, COPD, cancer, angioten-
sin-converting enzyme inhibitor (ACEI) or angiotensin
receptor blocker (ARB) use, proteinuria, index eGFR,
slope of eGFR decline in the 24 months before index
eGFR, blood urea nitrogen, serum bicarbonate, potassium,
calcium, phosphorus, hemoglobin, albumin, and systolic
and diastolic BP were entered based on their biological
plausibility as predictors based on previous studies.
A final model was developed using backward step-
wise selection based on the Akaike information criterion
(AIC) and bootstrap sampling (N = 100). Interaction terms
were evaluated. Nonlinearity was evaluated using
restricted cubic splines. Colinearity was assessed by evalu-
ating variance inflation factors. The proportional hazards
assumption was tested using cox.zph in R (www.R-
project.org), and no violations were detected. There were
no missing data for most variables and fewer than 10%
missing data except for phosphorus, which was unavail-
able for 37% of subjects. Primary analyses in the develop-
mental cohort were conducted using complete cases (82%
complete when phosphorus not considered). Secondary
analyses were conducted after imputing missing data using
single imputation. In the validation cohort, missing data
were imputed before validation using single imputation to
compare the new risk score with the Tangri score, which
includes phosphorus.11
A risk score based on the final model was calculated
for subjects in the validation cohort, and model perfor-
mance was evaluated using the Harrell C-index. Calibra-
tion was assessed by graphing the predicted and observed
rates according to decile of risk score, and a risk score
based on the work by Tangri and colleagues was calcu-
lated and performance evaluated by calculating Harrell
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C-index for the developmental and validation cohorts.11
The Tangri model was chosen because it was the most-
recent model developed to predict ESRD. Net reclassifica-
tion improvement from Tangri’s model to the VA risk
score was calculated.12 Secondary analyses compared the
risk model developed using Cox models to models devel-
oped using penalized estimation and competing risks
regression.13 Statistical analyses were conducted using R
2.12.2 (www.R-project.org).
RESULTS
There were 151,783 individuals at the Cleveland VA with
an outpatient eGFR between January 1, 2002, and January
1, 2009. Of these, 7,204 had at least one eGFR of less
than 30 mL/min per 1.73 m2; 1,866 had an eligible index
eGFR of less than 30 mL/min per 1.73 m2, were aged 65
and older, and did not have pre-existing ESRD or a kidney
transplant and were included in the present analyses (Fig-
ure 1).
Medical records were reviewed for 541 individuals
who met at least one criterion for chart review (hemodial-
ysis note, ICD-9 code, eGFR <15 mL/min per 1.73 m2 at
baseline or during follow-up or previously noted to have
ESRD in the database). To evaluate the sensitivity of these
criteria for identifying ESRD, the medical record was
reviewed for an additional 20 individuals with the lowest
follow-up eGFR of greater than 15 mL/min per 1.73 m2
and for 15 random additional subjects whose lowest
follow-up eGFR was between 16 and 30 mL/min per
1.73 m2. No cases of ESRD were identified in these addi-
tional chart reviews, an indication that the criteria for
chart review were sensitive.
Of the 1,866 participants in the developmental cohort,
77 developed ESRD, as adjudicated according to investiga-
tors blinded to VA risk score, and 276 died. The rate of
ESRD did not change over time. The baseline characteris-
tics for subjects in the developmental and validation
cohorts are shown in Table 1. The average decline in GFR
during the 2 years before the index eGFR was 6.9 mL/min
per 1.73 m2/year (95% confidence interval = 5.9–25.8).
A number of factors were associated with greater risk of
ESRD, including younger age, black race, CHF, high BP,
low eGFR, proteinuria, and low bicarbonate (Table 2).
The final model included index eGFR, age, CHF, aver-
age of last five clinic systolic BP measurements, most
recent potassium and albumin, and interactions between
age and eGFR and eGFR and CHF (Table 2). Similar
results were obtained when CHF was defined according to
one or more ICD-9 codes and when death was treated as a
competing risk (data not shown).14 Low potassium
remained a significant risk factor when ACEI, ARB, and
diuretic use were forced into the model. The bootstrap-
corrected C-index in the developmental cohort was 0.854,
indicating excellent predictive ability. There was no signifi-
cant nonlinearity or colinearity. The formula for calculat-
ing the risk for ESRD at 1 year based on the coefficients
from the final Cox model is shown in Appendix 1. Second-
ary analysis after imputing missing data produced a final
model with the same predictors. A model developed using
penalized estimation did not improve predictive ability
(net reclassification improvement = 3.2%; P = .34).
Hazard ratios were similar when calculated using Cox
proportional hazards regression and competing risks
regression (Table S1).
There were 819 participants in the validation cohort,
of whom 33 developed ESRD and 178 died. A risk score
based on the formula in Appendix 1 was calculated for
Figure 1. Participant flow for developmental cohort.
eGFR = estimated glomerular filtration rate.
Table 1. Baseline Characteristics of the Developmental
and Validation Cohorts
Characteristic
Developmental
Cohort,
n = 1,866
Validation
Cohort,
n = 819
Developed ESRD 77 (4.1) 33 (4.0)
Died without developing ESRD 276 (14.8) 178 (21.7)
Age, mean  SD 77.5  6.4 78.1  6.4
Black, n (%) 202 (11.8) 69 (8.4)
Male, n (%) 1,773 (95) 801 (97.8)
Past medical history, n (%)
Diabetes mellitus 922 (49.4) 307 (37.5)
Coronary artery disease 242 (13.0) 99 (12.1)
Congestive heart failure 188 (10.1) 88 (10.7)
Cancer 412 (22.1) 221 (27.0)
Average of last 5 clinic systolic
blood pressure measurements,
mmHg, mean  SD
144.1  19.8 138.8  19.2
Index eGFR, mL/min per
1.73 m2, mean  SD
25.0  4.3 24.9  4.3
25.0–30.0 1,143 (61.3) 511 (62.4)
20.0–24.9 499 (26.7) 194 (23.7)
<20 224 (12.0) 114 (13.9)
Proteinuria, n (%) 693 (37.1) 316 (38.6)
Potassium, mEq/L, mean  SD 4.68  0.6 4.66  0.6
Bicarbonate, mEq/L, mean  SD 24.2  3.9 25.5  4.5
Serum albumin, g/dL, mean  SD 3.83  0.5 3.76  0.5
Calcium, mg/dL, mean  SD 9.10  0.6 9.01  0.6
Phosphorus, mg/dL, mean  SD 3.80  0.7 3.81  0.9
Angiotensin-converting enzyme
inhibitors or angiotensin receptor
blocker use, n (%)
1,215 (65.1) 455 (55.6)
Conversion factors for units: estimated glomerular filtration rate (eGFR)
in mL/min per 1.73 m2 to mL/s per 1.73 m2 9 0.01667; serum albumin
in g/dL to g/L 9 10; serum calcium in mg/dL to mmol/L 9 0.2495; serum
phosphorus in mg/dL to mmol/L 9 0.3229. No conversion necessary for
serum potassium or bicarbonate in mEq/L to mmol/L.
SD = standard deviation; ESRD = end stage renal disease.
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subjects in the validation cohort. The risk for developing
ESRD at 1 year was 0.08% in participants in the lowest
tertile (VA risk score <0.7%), 2.7% in the middle tertile,
and 11.3% in the highest tertile (VA risk score >2.9%;
P < .001; Figure 2A). The risk for ESRD at 1 year for sub-
jects in the highest quintile (VA risk score >5.6%) was
14%. The C-index for the risk score in the validation sam-
ple was 0.823, indicating excellent predictive ability.
A recently published risk score (Tangri Model 6) was
calculated for subjects in the development and validation
cohorts.11 The C-index for the Tangri model was 0.780 in
both cohorts, indicating very good predictive ability. ESRD
event-free survival in the validation sample for subjects
according to tertile of Tangri risk score is shown in Fig-
ure 2B. Net reclassification improvement based on tertiles
from the Tangri model to tertiles based on the VA risk
score was 5.9% (P = .45).
DISCUSSION
A model to assess risk for ESRD at 1 year in elderly adults
with advanced CKD was developed and validated. The
model included age, CHF, systolic BP, eGFR, potassium,
and albumin and had excellent predictive ability in the val-
idation cohort (C-index 0.823). A recently published
model for predicting ESRD also had very good predictive
ability in the developmental and validation cohorts
(C-index 0.78).11 These models allow for identification of
individuals at low risk of progression to ESRD within
1 year.
In elderly adults, CKD is an important and growing
public health problem. Optimal clinical management of
CKD requires assessment of the risk for development of
ESRD. Previous studies have shown that the risk of ESRD
associated with advanced CKD is attenuated in elderly
adults.4,5,11,14–18 The risk of ESRD evaluated in a popula-
tion of U.S. veterans was similar to that reported here.4 At
all levels of eGFR, risk of ESRD decreased with advancing
age.4 This lower risk for ESRD is in part due to the greater
competing risk for all-cause mortality, and elderly adults
are less likely to receive renal replacement therapy even
when they advance to Stage V CKD; this may be due in
part to clinical uncertainty regarding the competing risks
for death and ESRD in elderly adults with advanced
CKD.19 Given the lower risk for ESRD, the current study
sought to develop a clinically meaningful tool to assess
risk of progression to ESRD in elderly adults with
advanced CKD. The risk score could be used to inform
decisions regarding renal replacement therapy such as
referrals and procedures for dialysis access placement.
The VA risk score includes variables previously
identified as risk factors for renal function decline
Table 2. Risk of End-Stage Renal Disease in the
Developmental Cohort
Variable
Unadjusted Final Modela
Hazard Ratio
(95% Confidence Interval)b
Age 0.71 (0.56–0.90) 0.60 (0.42–0.86)
Black 2.72 (1.59–4.65)
Diabetes mellitus 1.18 (0.75–1.85)
Congestive heart failure 2.59 (1.50–4.50) 4.72 (2.24–9.94)
Average of last five clinical
SBP measurements
1.33 (1.07–1.66) 1.41 (1.12–1.77)
eGFR 0.42 (0.37–0.48) 0.31 (0.25–0.37)
Proteinuria 2.41 (1.53–3.79)
Urea nitrogen 1.55 (1.32–1.82)
Potassium 0.78 (0.62–0.98) 0.74 (0.58–0.93)
Bicarbonate 0.78 (0.62–0.99)
Albumin 0.65 (0.53–0.80) 0.71 (0.56–0.89)
Calcium 0.67 (0.57–0.78)
Phosphorus 1.54 (1.23–1.93)
Hemoglobin 0.53 (0.42–0.67)
Angiotensin-converting
enzyme inhibitors or
angiotensin receptor
blocker use
0.79 (0.50–1.25)
a Estimated glomerular filtration rate (eGFR) by congestive heart failure
interaction term P = .009; eGFR by age interaction term P = .01.
Adjusted to median values: eGFR of 26.1, no heart failure, and age of
77.7 years.
b Associated with a 1–standard deviation increase for continuous variables
(6.4 years for age, 19.8 mmHg for systolic blood pressure (SBP),
0.62 mEq/L for potassium, and 0.46 g/dL for albumin).
VA Risk Score Tangri/JAMA Risk Score
Number at risk: Number at risk:
273               265              254                250               244               233               225            273  264              254                247               239                232              219
273               257              249                242               230               217               203            273  262              248                237               229                217              207
273               253              233                211               198               191               175            273  249              234                219               204                192              177
0           60         120         180         240        300        360
Time to event (days)
0            60         120         180         240        300       360
Time to event (days)
Log Rank test P < 0.0001
C index = 0.823
Log Rank test P < 0.0001
C index = 0.780
First tertile
Second tertile
Third tertile
First tertile
Second tertile
Third tertile
A B
Risk ScoreRisk Score
1.00
0.95
0.90
0.85
0.80
Figure 2. End-stage renal disease–free survival in the validation cohort. (A) Veterans Affairs (VA) risk score. (B) Tangri risk score.
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and ESRD: younger age,4,5,11,15–18 low baseline
eGFR,11,14–17,20–22 high clinical systolic BP,5,14 CHF,23
and low serum albumin.11,21 CHF may predispose to
ESRD through episodes of acute kidney injury from vol-
ume changes associated with episodes of decompensated
heart failure, although CHF may also be a marker of
underlying cardio- and renovascular disease. Low potas-
sium may be a marker of poor nutritional status and
was associated with low albumin. Alternatively, low
potassium may simply be a marker of other risk factors;
in the developmental cohort, low potassium was associ-
ated with black race, low eGFR, low albumin, diuretic
use, and lack of ACEI and ARB use but not CHF or
systolic BP. A notable exclusion from the final model is
proteinuria, a well-defined risk factor for
ESRD.5,11,14,17,20–22 The lack of standard assessment
may play a role—10% of subjects had no assessment
for proteinuria, and a urine albumin to creatinine ratio
was available for fewer than one-third of subjects.
Therefore, measurement of proteinuria in a majority of
subjects was based on semiquantitative methods that are
dependent on urine concentration and are not as accu-
rate an assessment of proteinuria.
In addition to developing and validating a new
model, the predictive ability of a recently published risk
score was also evaluated (Tangri Model 6).11 The Tangri
model and the VA risk score include eGFR, age, and
serum albumin. The Tangri model also includes urine
albumin to creatinine ratio and serum phosphorus, bicar-
bonate, and calcium. There are other important differ-
ences between the two scores. Tangri and colleagues
provided a model to predict risk over a 5-year time period
(compared with 1 year in this study), and their cohort
included individuals with a baseline eGFR less than
60 mL/min per 1.73 m2, whereas the current study
included only those with an eGFR less than 30 mL/min
per 1.73 m2. A calculator for predicting 2-year risk of
ESRD based on the Tangri model is available online.11
The Tangri model does not include BP, a variable that is
included in the current model. This may be due to mea-
surement based on only one clinic BP at the time of the
initial nephrology visit in the study by Tangri. For the
current study, BP was based on an average of up to five
clinic measurements before the index GFR, probably a
more-accurate assessment of BP. Despite the differences in
cohort characteristics and length of follow-up, the Tangri
model had good predictive ability in the developmental
and validation cohorts.
Previous investigators have developed prediction models
for a variety of kidney disease outcomes, including incident
CKD,24,25 progression of CKD,26,27 and ESRD,5,11,15–17,20–22,28
but the models have limited utility for management of
advanced CKD. Many of the models predict outcomes other
than ESRD.24–27 In addition, the period over which ESRD is
predicted ranges from 2.5 to 10 years, a longer time frame than
required for access placement.5,15–17,20–22,28 Finally, some mod-
els include individuals with normal kidney function or mild
CKD.11,15,16,20–22,28 Therefore, although previous investigators
evaluated risk factors for ESRD in various populations, before
the current study, no prediction model was available to evalu-
ate risk of ESRD at 1 year in older adults with advanced
CKD.
This prediction model has a number of strengths.
First, the 1-year time period over which risk for ESRD
was assessed is clinically meaningful in that it is approxi-
mately the time required for preparation for hemodialysis.
Previous prediction models have included follow-up rang-
ing from 2.5 to 10 years.5,15–17,20–22,28 The current model
also included only subjects in whom planning for renal
replacement therapy is recommended: those with advanced
CKD (eGFR <30 mL/min per 1.73 m2).7 Another strength
is the use of commonly available data from “real-world
settings” and the development of a tool to help clinicians
and individuals “choose the option that best fit(s) the indi-
vidual’s needs and preferences”: two of the pillars of com-
parative effectiveness research.29 The VA risk score could
be incorporated into electronic medical records, similar to
the reporting of eGFR with creatinine results. The current
study included a large cohort of individuals with advanced
CKD. Finally, a significant strength was the validation of
the prediction model in a separate cohort.30
A few limitations need to be considered. As with most
VA studies, the cohort was predominantly male. The retro-
spective nature of the study precluded formal assessment
of comorbidities and prospective collection of urine and
serum samples for laboratory analyses. The diagnosis of
heart failure was based on ICD-9 codes rather than echo-
cardiographic examination. ICD-9-based diagnosis allows
for automated risk score calculation using electronic medi-
cal records. Time to ESRD was adjudicated using chart
review; confirmation by linkage to the U.S. Renal Data
System was not performed, but the authors are fairly cer-
tain about the specificity of the diagnosis, and the chance
that incident ESRD cases were “missed” is low. Proteinuria
was not found to be a predictor in adjusted models despite
strong evidence from prior studies demonstrating it to be a
predictor of ESRD. Finally, although the prediction model
was evaluated in a validation cohort, similarities between
the development and validation cohorts necessitate further
validation in cohorts with varying characteristics.
This study makes an important contribution and
provides a new tool that can be used in the clinical setting.
The excellent predictive ability of the model will provide
clinicians and patients with much needed information as
they contemplate the multitude of decisions surrounding
renal replacement therapy, a process that is difficult for
patients and nephrologists.31 The VA risk score can be
used to identify older adults at low risk of development of
ESRD in the next year. In consultation with the individual,
clinicians may elect to defer ESRD preparation and access
placement for individuals in the lower and middle tertiles
(risk score <2.9%). Individuals with low likelihood of
ESRD can avoid the potential risks of vascular access
placement (e.g., vascular insufficiency, steal syndrome, and
high-output heart failure). This is especially important
given recent evidence from the Initiating Dialysis Early
and Late Study indicating no benefit of “early” initia-
tion.32 Alternatively, individuals at higher risk of ESRD
(top quintile, risk score >5.6%, observed risk 14%) may
consider preparation for ESRD and placement of dialysis
access. This study does not aim to define when dialysis
should be initiated but to provide a tool to better inform
the planning for dialysis, but it is only one tool; clinical
decisions at the individual level need to take into account
766 DRAWZ ET AL. MAY 2013–VOL. 61, NO. 5 JAGS
the circumstances for each individual. Finally, research is
necessary to assess the ability of these models to improve
long-term outcomes in advanced CKD and increase rates
of appropriate vascular access placement.
CONCLUSION
In summary, a model was developed and validated to pre-
dict risk for ESRD at 1 year in elderly adults with
advanced CKD. The score uses commonly available clini-
cal variables and may be a tool for risk stratification that
individuals and physicians can use to inform decisions
regarding planning for ESRD in older adults with
advanced CKD.
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APPENDIX 1. VETERANS AFFAIRS RISK SCORE
FORMULA
To calculate risk of end-stage renal disease at 1 year, calculate
L as follows:
L = 2.373310 + 0.2334318 9 index estimated glo-
merular filtration rate (eGFR) 2.108974 9 1 if positive
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for congestive heart failure (CHF) + 0.09131896
9 age0.7468557 9 albumin0.4961119 9 potassium +
0.01726844 9 average last 5 systolic blood pressure mea-
surements + 0.1402834 9 index eGFR 9 1 if positive for
CHF0.006568763 9 index eGFR 9 Age
Risk of ESRD at 1 year is then calculated a: 10.983^
(2.71828^L)
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